In summary, aPS/PT, measured with either in-house or commercial assay, in addition to aCL and anti-β2GPI antibodies, could represent an additional marker in patients with clinical manifestations of APS. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.